Treatment of Helicobacter pylori

Helicobacter

Volumn 12, Issue SUPPL. 1, 2007, Pages 31-37

  Egan, B J ^a   Katicic, M ^b   O'Connor, H J ^a   O'Morain, C A ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

^b University of Zagreb   (Croatia)

Author keywords

Adjuvant therapy; Antimicrobial resistance; Eradication failure; Eradication therapy; Sequential therapy

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; ESOMEPRAZOLE; LACTOFERRIN; LEVOFLOXACIN; METRONIDAZOLE; OMEPRAZOLE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RABEPRAZOLE; RANITIDINE BISMUTH CITRATE; RIFAXIMIN; TETRACYCLINE; TINIDAZOLE;

ANTIBIOTIC RESISTANCE; BACILLUS; BACTERIAL GROWTH; BIFIDOBACTERIUM; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERADICATION THERAPY; GASTROINTESTINAL SYMPTOM; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LACTOBACILLUS; MULTIDRUG RESISTANCE; NONHUMAN; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SACCHAROMYCES BOULARDII; TREATMENT DURATION; TREATMENT FAILURE;

ADULT; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PROTON PUMPS; TREATMENT OUTCOME;

HELICOBACTER PYLORI;

EID: 34548155016     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2007.00538.x     Document Type: Review

References (50)

1. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - The Maastricht III Consensus Report. Gut 2007 56 : 772 81.
2. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004 53 : 1374 84.
3. Fischbach L, Evans EL. Meta-analysis: effect of antibiotic resistance on treatments for H. pylori. Aliment Pharmacol Ther 2007 ahead of print.
4. Gerrits MM, van Vliet AH, Kuipers EJ, Kusters JG. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infect Dis 2006 6 : 699 709.
5. Meyer JM, Silliman NP, Wang W, Siepman NY, Sugg JE, Morris D, Zhang J, Bhattacharyya H, King EC, Hopkins RJ. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann Intern Med 2002 136 : 13 24.
6. Duck WM, Sobel J, Pruckler JM, et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 2004 10 : 1088 94.
7. Megraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007 20 : 280 322. Review.
8. Glupczynski Y, Megraud F, Lopez-Brea M, et al. European multicenter survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2000 11 : 820 3.
9. Zullo A, Perna F, Hassan C, Ricci C, Saracino I, Morini S, Vaira D. Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. Aliment Pharmacol Ther 2007 25 : 1429 34.
10. Bogaerts P, Berhin C, Nizet H, Glupczynski Y. Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter 2006 11 : 441 5.
11. Janssen MJ, Hendrikse L, de Boer SY, Bosboom R, de Boer WA, Laheij RJ, Jansen JB. Helicobacter pylori antibiotic resistance in a Dutch region: trends over time. Neth J Med 2006 64 : 191 5.
12. Egan BJ, O'Morain CA. A historical perspective on Helicobacter gastroduodenitis and its complications. Best Pract Res Clin Gastroenterol 2007 21 : 335 46. Review.
13. Paoluzi P, Iacopini F, Crispino P, et al. 2-week triple therapy for Helicobacter pylori infection is better than 1-week in clinical practice: a large prospective single-center randomized study. Helicobacter 2006 11 : 562 8.
14. Katicic M, Ticak M, Prskalo M, Naumovski-Mihalic S, Filipec-Kanizaj T, Skurla B, Sabaric B, Colic-Cvrlje V, Papa B. Eradication of Helicobacter pylori infection with two triple therapy regimes of 7, 10, and 14 days: four year experience. Helicobacter 2006 2 : A11. 05 : p386.
15. Zagari RM, Bianchi-Porro G, Fiocca R, Gasbarrini G, Roda E, Bazzoli F. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut 2007 56 : 475 9.
16. Kim BG, Lee DH, Ye BD, et al. Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea. Helicobacter 2007 12 : 31 5.
17. Kadayifci A, Buyukhatipoglu H, Cemil Savas M, Simsek I. Eradication of Helicobacter pylori with triple therapy: an epidemiologic analysis of trends in Turkey over 10 years. Clin Ther 2006 28 : 1960 6. Review.
18. Nista EC, Candelli M, Zocco MA, Cremonini F, Ojetti V, Finizio R, Spada C, Cammarota G, Gasbarrini G, Gasbarrini A. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol 2006 101 : 1985 90.
19. Antos D, Schneider-Brachert W, Bästlein E, et al. 7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity. Helicobacter 2006 11 : 39 45.
20. Gasbarrini A, Lauritano EC, Nista EC, et al. Rifaximin-based regimens for eradication of Helicobacter pylori: a pilot study. Dig Dis 2006 24 : 195 200.
21. Gisbert JP, Fernandez Bermejo M, Molina Infante J, Perez Gallardo B, Prieto Bermejo AB, Mateos Rodriguez JM, Robledo Andres P, Gonzalez Garcia G. First-line triple therapy with levofloxacin for Helicobacter pylori eradication 2007 ahead of print.
22. Dore MP, Maragkoudakis E, Pironti A, Tadeu V, Tedde R, Realdi G, Delitala G. Twice-a-day quadruple therapy for eradication of Helicobacter pylori in the elderly. Helicobacter 2006 11 : 52 5.
23. Calvet X, Ducons J, Guardiola J, Tito L, Andreu V, Bory F, Guirao R Group for Eradication Studies from Catalonia Aragón (Gresca). One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial. Aliment Pharmacol Ther 2002 16 : 1261 7.
24. Vaira D, Zullo A, Vakil N, Gatta L, Ricci C, Perna F, Hassan C, Bernabucci V, Tampieri A, Morini S. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007 146 : 556 63.
25. Scaccianoce G, Hassan C, Panarese A, Piglionica D, Morini S, Zullo A. Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen. Can J Gastroenterol 2006 20 : 113 7.
26. Zullo A, Gatta L, De Francesco V, Hassan C, Ricci C, Bernabucci V, Cavina M, Ierardi E, Morini S, Vaira D. High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. Aliment Pharmacol Ther 2005 21 : 1419 24.
27. De Francesco V, Zullo A, Hassan C, et al. The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study. Dig Liver Dis 2004 36 : 322 6.
28. Lamouliatte H, Mégraud F, Delchier JC, et al. Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. Aliment Pharmacol Ther 2003 18 : 791 7.
29. Kawai T, Kawakami K, Kataoka M, et al. Comparison of efficacies of dual therapy and triple therapy using rabeprazole in second-line eradication of Helicobacter pylori in Japan. Aliment Pharmacol Ther 2006 24 (Suppl. 4 16 22.
30. Shirai N, Sugimoto M, Kodaira C, Nishino M, Ikuma M, Kajimura M, Ohashi K, Ishizaki T, Hishida A, Furuta T. Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy. Eur J Clin Pharmacol 2007 63 : 743 9.
31. Gisbert JP, Pajares JM. Review article: Helicobacter pylori 'rescue' regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002 16 : 1047 57. Review.
32. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006 23 : 35 44.
33. Wu DC, Hsu PI, Chen A, et al. Randomized comparison of two rescue therapies for Helicobacter pylori infection. Eur J Clin Invest 2006 36 : 803 9.
34. Gisbert JP, Gisbert JL, Marcos S, Moreno-Otero R, Pajares JM. Levofloxacin- vs. ranitidine bismuth citrate-containing therapy after H. pylori treatment failure. Helicobacter 2007 12 : 68 73.
35. Qasim A, Sebastian S, Thornton O, Dobson M, McLoughlin R, Buckley M, O'Connor H, O'Morain C. Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther 2005 21 : 91 6.
36. Gisbert JP, Gisbert JL, Marcos S, Moreno-Otero R, Pajares JM. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment Pharmacol Ther 2006 24 : 1469 74.
37. de Bortoli N, Leonardi G, Ciancia E, et al. Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. Am J Gastroenterol 2007 102 : 951 6.
38. Fuller R. Probiotics in human medicine. Gut 1991 32 : 439 42. Review.
39. Lesbros-Pantoflickova D, Corthésy-Theulaz I, Blum AL. Helicobacter pylori and probiotics. J Nutr 2007 137 (3 Suppl. 2 812S 8S.
40. Gotteland M, Brunser O, Cruchet S. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? Aliment Pharmacol Ther 2006 23 : 1077 86. Review.
41. Tursi A, Elisei W, Brandimarte G, Giorgetti GM, Modeo ME, Aiello F. Effect of lactoferrin supplementation on the effectiveness and tolerability of a 7-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection. Med Sci Monit 2007 13 : CR187 190.
42. Di Mario F, Aragona G, Dal Bó N, et al. Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. Aliment Pharmacol Ther 2006 23 : 1235 40.
43. Cremonini F, Di Caro S, Covino M, Armuzzi A, Gabrielli M, Santarelli L, Nista EC, Cammarota G, Gasbarrini G, Gasbarrini A. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002 97 : 2744 9.
44. Nista EC, Candelli M, Cremonini F, Cazzato IA, Zocco MA, Franceschi F, Cammarota G, Gasbarrini G, Gasbarrini A. Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. Aliment Pharmacol Ther 2004 20 : 1181 8.
45. Tong JL, Ran ZH, Shen J et al. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007 25 : 155 68.
46. Suzuki T, Matsuo K, Ito H, Sawaki A, Hirose K, Wakai K, Sato S, Nakamura T, Yamao K, Ueda R. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med 2006 119 : 217 224.
47. Suzuki T, Matsuo K, Sawaki A, et al. Influence of smoking and CYP2C19 genotypes on H. pylori eradication success. Epidemiol Infect 2007 135 : 171 6.
48. Koivisto TT, Rautelin HI, Voutilainen ME, Heikkinen MT, Koskenpato JP, Färkkilä MA. First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance: results of three eradication regimens. Aliment Pharmacol Ther 2005 21 : 773 82.
49. Murray LJ, Lane AJ, Harvey IM, Donovan JL, Nair P, Harvey RF. Inverse relationship between alcohol consumption and active Helicobacter pylori infection: the Bristol Helicobacter project. Am J Gastroenterol 2002 97 : 2750 5.
50. Baena JM, López C, Hidalgo A, Rams F, Jiménez S, García M, Hernández MR. Relation between alcohol consumption and the success of Helicobacter pylori eradication therapy using omeprazole, clarithromycin and amoxicillin for 1 week. Eur J Gastroenterol Hepatol 2002 14 : 291 6.